Kantar Health Blog

  • User Not Found
    Despite the high utilization of Tarceva in the United States, it currently is not FDA approved in the first-line setting. This lack of approval created an opportunity for afatinib to enter this market without directly challenging the market leader in a head-to-head clinical trial. The LUX-LUNG-3 results might push Roche into finally filing for Tarceva approval in the US. ASCO 2012
    Continue Reading > | Go comment! | Share
  • User Not Found
    This environment highlighted the need for clinical data asking whether continued VEGF inhibition would provide survival benefit to patients, and are addressed by two trials at ASCO 2012: TML (Treatment across Multiple Lines; ML18147) which examined the efficacy of Avastin and chemotherapy following first-line Avastin and chemotherapy. ASCO 2012
    Continue Reading > | Go comment! | Share
  • Natalie Bush
    T-DM1 is designed to take advantage of the targeted nature of the antibody to selectively deliver the cytotoxic agent to HER2+ breast cancer cells. Roche is hoping that T-DM1 will further expand their franchise in HER2+ breast cancer. Roche’s other product, Herceptin (trastuzumab), currently dominates the HER2+ market, with about 70% utilization in front-line HER2+ metastatic breast cancer patients. ASCO 2012
    Continue Reading > | Go comment! | Share
  • Stephanie Hawthorne
    In ovarian cancer, Avastin plus chemotherapy achieved significant improvement in primary endpoint of median progression-free survival (mPFS= 6.7 months in Avastin plus chemotherapy versus 3.4 months in control arm; HR 0.48, p<0.001). ASCO 2012
    Continue Reading > | Go comment! | Share
  • Renal Cell Carcinoma: How to Stand Out in a Crowd

    by User Not Found | Jun 2, 2012
    User Not Found
    There are currently 7 agents (excluding cytokines) approved for use in renal cell carcinoma (RCC), 5 of which are approved for use in the first-line setting, of which 4 are VEGF pathway inhibitors. With so many options, and few definitively differentiating factors, how is a physician (or patient) to choose the best course of therapy?
    Continue Reading > | Go comment! | Share